Waldenström Macroglobulinemia
Paraproteinemia and Related Disorders, Page: 211-228
2022
- 78Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures78
- Readers78
- 78
Book Chapter Description
Waldenström macroglobulinemia (WM) is a rare, low-grade lymphoplasmacytic lymphoma involving the bone marrow, lymph nodes, and spleen with monoclonal immunoglobulin M (IgM) protein secretion (Yun et al., Clin Lymphoma Myeloma Leuk. 17:252–62, 2017). Other low-grade lymphoproliferative disorders may also present with IgM monoclonal protein and should be excluded. Although asymptomatic in some cases, patients may suffer from cytopenia, lymphadenopathy, splenomegaly, or hepatomegaly. Raised serum monoclonal IgM can result in hyperviscosity syndrome. Approximately 1000–1500 new WM cases are diagnosed every year in the United States (Sekhar et al., Leuk Lymphoma. 53:1625–6, 2012). Although incurable, treatment is needed in symptomatic patients. Plasmapheresis is used in case of hyperviscosity. Alkylating agents, nucleoside analogs, anti-CD20 monoclonal antibodies, and/or Bruton tyrosine kinase inhibitors (BTKi), among other agents, single or in combination, have all been used to control clinical manifestations and reduce IgM levels.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85160119023&origin=inward; http://dx.doi.org/10.1007/978-3-031-10131-1_14; https://link.springer.com/10.1007/978-3-031-10131-1_14; https://dx.doi.org/10.1007/978-3-031-10131-1_14; https://link.springer.com/chapter/10.1007/978-3-031-10131-1_14
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know